Barbara Ann Karmanos Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Barbara Ann Karmanos Cancer Institute sits in the top decile of US sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count).
Barbara Ann Karmanos Cancer Institute: 139 sponsored US clinical trials, 16 recruiting.
Barbara Ann Karmanos Cancer Institute sponsors 139 registered US clinical trials on ClinicalTrials.gov, 16 of them currently recruiting, and 100 completed. 1 of these trials are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 4 trials.
Top-decile sponsor footprint
Barbara Ann Karmanos Cancer Institute ranks in the top decile of sponsors by registered trial count (#202 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
100 of 120 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
139 total, page 1 of 3
A Study of the TheraBionic P1 Device in Breast Cancer
NCT07218432
Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
NCT07436078
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
NCT07118202
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
NCT07098299
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
NCT07130903
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
NCT07095114
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
NCT06576115
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
NCT06908629
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
NCT06420167
Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
NCT06107738
Dietary Reporting in the Amyloidoses
NCT05738005
A Provider Intervention to Reduce Financial Toxicity in Patients With Cancer Through Improved Treatment Cost Discussions
NCT07042191
F-Tryptophan PET/CT in Human Cancers
NCT05556473
C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)
NCT03750981
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
NCT02178163
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
NCT00935090
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
NCT04479267
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
NCT03147885
Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression
NCT07672431
Ask Questions (ASQ):Implementation of a Communication Intervention
NCT05025748
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
NCT05028374
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
NCT04397679
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
NCT04282343
Medical Physics Direct Patient Care for the Improvement of Patient Understanding of Care
NCT04266522
ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT04159896
Reducing Metabolic Syndrome Among Breast Cancer Survivors
NCT03719677
Tobacco Cessation Intervention
NCT03657511
Feasibility and Utilization of an Application-based Question Prompt List
NCT03676920
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
NCT03453489
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03406858
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo
NCT03421652
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT03456804
Music in Reducing Distress in Participants with Cancer During Chemotherapy Treatment
NCT03683420
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
NCT02819024
Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
NCT02824029
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
NCT02568449
Low-Level Laser Therapy for Prevention of Oral Mucositis
NCT02723604
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
NCT02620865
Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
NCT02520115
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
NCT02472275
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
NCT01609816
MK-3475 as Maintenance Therapy in Extensive Stage SCLC
NCT02359019
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
NCT01958372
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
NCT02145078
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
NCT02058706
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
NCT01987596
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
NCT01812668
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
NCT01728259
Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer
NCT01698658
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
NCT01643603
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 33 |
| Phase 2 | 66 |
| Phase 3 | 1 |
What is open in the Barbara Ann Karmanos Cancer Institute pipeline
16 recruiting of 139 indexed (12% open); 100 completed (72%).
Phase mix: 1 late (III/IV) vs 99 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Barbara Ann Karmanos Cancer Institute: open-pipeline peers nationwide
Peers matched on 139 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Barbara Ann Karmanos Cancer Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 139 trials (± recruiting share)
- Centers for Disease Control and Prevention · 139 trials · 2% recruiting
- Mclean Hospital · 140 trials · 19% recruiting
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 138 trials · 3% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Abbott Diabetes Care · 12% recruiting · 26 trials
- Medtronic Vascular · 12% recruiting · 26 trials
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
- VA Connecticut Healthcare System · 12% recruiting · 26 trials
Related
What to do with this Barbara Ann Karmanos Cancer Institute page
139 registered trials is a research-attention snapshot, not an endorsement of Barbara Ann Karmanos Cancer Institute or any single study.
- 16 of Barbara Ann Karmanos Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Barbara Ann Karmanos Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Barbara Ann Karmanos Cancer Institute pipeline card: 139 registered trials from official public datasets.Report a data error.